Pharmacopsychiatry 2019; 52(01): 24-31
DOI: 10.1055/s-0044-101466
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials

Wei Zheng*
1   The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
,
Qing-E Zhang*
2   The National Clinical Research Center for Mental Disorders, China & Center of Depression, Beijing Institute for Brain Disorders & Mood Disorders Center, Beijing Anding Hospital, Capital Medical University, Beijing, China
,
Dong-Bin Cai
3   Clinics of Chinese Medicine, First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China
,
Xin-Hu Yang
1   The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
,
Gabor S. Ungvari
4   The University of Notre Dame Australia / Graylands Hospital, Perth, Australia
,
Chee H. Ng
5   Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
,
Ren-Rong Wu
6   Mental Health Institute of the Second Xiangya Hospital & National Technology Institute of Psychiatry & Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, China
,
Yu-Tao Xiang
7   Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China
› Author Affiliations
Further Information

Publication History

received 11 July 2017
revised 25 November 2017

accepted 16 January 2018

Publication Date:
27 February 2018 (online)

Abstract

Introduction Weight gain is a common antipsychotic (AP)-related adverse drug reaction (ADR) that can increase the risk of cardiovascular diseases and premature mortality. This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia.

Methods Randomized controlled trials (RCTs) with meta-analyzable data were searched and retrieved by 2 independent investigators. RevMan software (version 5.3) was used to synthesize data, and to calculate the standardized or weighted mean differences and risk ratio with their 95% confidence intervals.

Results Six RCTs (n=732) were included and meta-analyzed. The metformin and lifestyle combination (MLC) group had significant reduction in weight and body mass index compared with the metformin group, lifestyle group, and placebo group. There was less frequent weight gain of≥7% in the MLC group over placebo. No other group differences in ADRs, total psychopathology, and all-cause discontinuation were found. In terms of study quality, 5 RCTs were open-labelled, 1 RCT had low risk allocation concealment, and 3 RCTs specifically described randomization methods.

Conclusion Combining metformin and lifestyle intervention shows significant effect in reducing AP-related weight gain. Higher quality and larger RCTs are needed to confirm these findings.

Review registration: CRD42017059198

* These authors contributed equally to this work.


Supporting Information

 
  • References

  • 1 Liu Z, Zheng W, Gao S. et al. Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: A meta-analysis. Shanghai Arch Psychiatry 2015; 27: 331-340
  • 2 Zheng W, Li XB, Tang YL. et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015; 35: 499-509
  • 3 Wu RR, Zhao JP, Jin H. et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185-193
  • 4 Zheng W, Zheng YJ, Li XB. et al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: Meta-analysis of randomized controlled trials. J Clin Psychopharmacol. 2016; 36: 628-636
  • 5 Curtis J, Watkins A, Rosenbaum S. et al. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry 2016; 10: 267-276
  • 6 Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520-1530
  • 7 Cooper SJ, Reynolds GP, Barnes T. et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016; 30: 717-748
  • 8 Zheng W, Xiang YQ, Ungvari GS. et al. Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2017; 37: 341-346
  • 9 Templeman LA, Reynolds GP, Arranz B. et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005; 15: 195-200
  • 10 Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1-4
  • 11 Yeo S, Walker JS, Caughey MC. et al. What characteristics of nutrition and physical activity interventions are key to effectively reducing weight gain in obese or overweight pregnant women? A systematic review and meta-analysis. Obes Rev. 2017; 18: 385-399
  • 12 Webb VL, Wadden TA. Intensive lifestyle intervention for obesity: principles, practices, and results. Gastroenterology 2017; 152: 1752-1764
  • 13 Sun Y, You W, Almeida F. et al. The effectiveness and cost of lifestyle interventions including nutrition education for diabetes prevention: A systematic review and meta-analysis. J Acad Nutr Diet 2017; 117: 404-421
  • 14 Forsberg KA, Bjorkman T, Sandman PO. et al. Physical health–a cluster randomized controlled lifestyle intervention among persons with a psychiatric disability and their staff. Nord J Psychiatry 2008; 62: 486-495
  • 15 Attux C, Martini LC, Elkis H. et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry 2013; 13: 60
  • 16 Alvarez-Jiménez M, Hetrick SE, González-Blanch C. et al. Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008; 193: 101-107
  • 17 Wu RR, Zhao JP, Guo XF. et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. Am J Psychiatry. 2008; 165: 352-358
  • 18 Wu RR, Zhang FY, Gao KM. et al. Metformin treatment of antipsychotic-induced dyslipidemia: An analysis of two randomized, placebo-controlled trials. Mol Psychiatry. 2016; 21: 1537-1544
  • 19 Klein DJ, Cottingham EM, Sorter M. et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006; 163: 2072-2079
  • 20 Mizuno Y, Suzuki T, Nakagawa A. et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophr Bull. 2014; 40: 1385-1403
  • 21 de Silva VA, Suraweera C, Ratnatunga SS. et al. Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry 2016; 16: 341
  • 22 Siskind DJ, Leung J, Russell AW. et al. Metformin for clozapine associated obesity: A systematic review and meta-analysis. PloS One 2016; 11: e0156208
  • 23 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009; 151: 264-269
  • 24 Baptista T, Martínez J, Lacruz A. et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Can J Psychiatry. 2006; 51: 192-196
  • 25 Baptista T, Rangel N, Fernández V. et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007; 93: 99-108
  • 26 Jarskog LF, Hamer RM, Catellier DJ. et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013; 170: 1032-1040
  • 27 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276
  • 28 Overall JE, Gorham DR. The brief psychiatric rating-scale. Psychol Rep. 1962; 10: 799-812
  • 29 Higgins J, Higgins J. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2008
  • 30 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
  • 31 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558
  • 32 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
  • 33 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12
  • 34 Balshem H, Helfand M, Schunemann HJ. et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401-406
  • 35 Atkins D, Best D, Briss PA. et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
  • 36 Chen JX, Wu SY, Lin R. et al. The efficacy of metformin in combination with life style intervention on body weight, blood lipid and blood glucose in schizophrenia during clozapine treatment. Sichuan Mental Health 2010; 23: 198-202
  • 37 Du YH, Lv HJ. Effect of metformin combined with behavioral intervention on body weight increasing and glucose and lipid metabolism disorder of schizophrenic patients. Journal of Xinxiang Medical University 2014; 31: 381-384
  • 38 Mi ZY, Shi XL. Metformin with behavior intervention in treatment of antipsychotic-induced metabolic disorders. China Pharmaceuticals 2014; 23: 87-89
  • 39 Wang XL. Metformin with lifestyle intervention in treatment of clozapine-induced metabolic disorders. Medica of China Family Physicians 2009; 12: 840-842
  • 40 Xia JX, Wang YB, Gan JG. et al. Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone. The Chinese Journal of Clinical Pharmacology 2011; 27: 417-419
  • 41 Mukundan A, Faulkner G, Cohn T. et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010; 12: CD006629
  • 42 Zheng W, Xiang YT, Xiang YQ. et al. Efficacy and safety of adjunctive topiramate for schizophrenia: A meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2016; 134: 385-398
  • 43 Zheng W, Yang XH, Cai DB. et al. Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. J Psychopharmacol. 2017; 31: 625-631
  • 44 Chittaranjan A. Use of metformin for cardiometabolic risks in psychiatric practice: Need-to-know safety issues. J Clin Psychiatry. 2016; 77: e1491-e1494
  • 45 Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL. et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry. 2006; 67: 1253-1260